Procurement comparison
IGF-1 LR3 Peptide Stacking: Research Protocol Comparison
IGF-1 LR3 + CJC-1295/Ipamorelin Upstream GH potentiation + direct IGF-1R activation GH secretagogue 6–8h before IGF-1 LR3 CJC 1–2mg/wk + Ipamorelin 200–300mcg + IGF-1 LR3 40–80mcg Elevated endogenous IGF-1 baseline amplifies exogenous analog receptor saturatio
Review the documented criteria directly; this page does not generate a winner or rating.
- IGF-1 LR3 + CJC-1295/Ipamorelin
- Upstream GH potentiation + direct IGF-1R activation
- GH secretagogue 6–8h before IGF-1 LR3
- CJC 1–2mg/wk + Ipamorelin 200–300mcg + IGF-1 LR3 40–80mcg
- Elevated endogenous IGF-1 baseline amplifies exogenous analog receptor saturation
- Most common stack in anabolic research. Requires precise timing to avoid redundancy
- IGF-1 LR3 + BPC-157
- IGF-1R signalling + VEGF/FGF modulation for tissue repair
- Concurrent administration
- BPC-157 250–500mcg/day + IGF-1 LR3 40–100mcg/day
- Orthogonal pathways. Protein synthesis + collagen deposition without receptor competition
- Ideal for musculoskeletal injury models. No cross-talk interference
- IGF-1 LR3 + MK-677
- Ghrelin receptor agonism (oral GH secretagogue) + exogenous IGF-1R activation
- MK-677 daily (evening) + IGF-1 LR3 morning administration
- MK-677 12.5–25mg/day + IGF-1 LR3 40–80mcg/day
- Sustained endogenous GH elevation + direct IGF receptor saturation
- MK-677's 24h half-life creates continuous upstream potentiation. Simpler than injectable GH secretagogues
- IGF-1 LR3 + Thymalin
- Direct IGF-1R activation + thymic peptide immune modulation
- Concurrent or alternating-day protocol
- Thymalin 5–10mg 2x/week + IGF-1 LR3 40–80mcg/day
- No receptor overlap. Anabolic signalling + T-cell maturation support
- Rarely studied outside immune-metabolic research. No interference but minimal direct synergy